According to the company's own published disclosures, these medications are "produced in FDA-regulated facilities" but are "not FDA-approved or evaluated for safety, efficacy, or quality." FDA-approved branded Ozempic is also listed on the platform at a higher price point
A trial published in the New England Journal of Medicine enrolled adults with a BMI (body mass index) of 30 or higher, or between 27 and 30 with weight-related conditions (e.g
Andres Splenser, MD, an endocrinologist at Memorial Hermann, who was not involved in this study, suggested that the link may have something to do with the relationship between mood and appetite, among other potential factors
This medication is sold in a few forms: Ozempic (injectable): approved in2017for lowering blood sugar levels in adults with type 2 diabetes, as well as reducing the risk of heart attack, stroke, or death in those with type 2 diabetes and heart disease Rybelsus (tablet): approved in2019as the first and only GLP-1 analog in pill form and indicated to improve blood sugar regulation in adults with type 2 diabetes Wegovy (injectable): approved in2021for weight management Use of Rybelsus and Ozempic for weight loss is considered However, to maintain the weight loss benefits of semaglutide, people need to continue taking it
Transdermal patches, by contrast, have not been evaluated in large human safety trials, so the incidence and severity of side effects remain unknown
